Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + N-803 +/- PD-L1 t-haNK Cells for Resectable HNSCC
NCT06161545Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2025
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
A Phase 2 trial of PD-L1 t-haNK, nogapendekin alfa inbakicept in head and neck squamous cell carcinoma (HNSCC), sponsored by National Cancer Institute. Started Sep 2025; status: recruiting.
02
Drugs
PD-L1 t-haNKnogapendekin alfa inbakicept
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06161545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06161545.